Add-back therapy in the treatment of endometriosis-associated pain

Errico Zupi, Marconi D, Daniela Marconi, Sbracia M, Marco Sbracia, Fulvio Zullo, Zullo F, Bonaventura De Vivo, B De Vivo, De Vivo B, Caterina Exacustos, Exacustos C, Giuseppe Sorrenti, Sorrenti G
Fertility and sterility · 2004 · vol. 82(5) , pp. 1303–1308 · doi:10.1016/j.fertnstert.2004.03.062 · PMID:15533351 · W2082587924
article OA: closed CC0 ⤵ 86 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

This study investigates the efficacy of add-back therapy in managing pain associated with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo determine the efficacy of GnRH analogue plus add-back therapy compared with GnRH analogue alone and estroprogestin in patients with relapse of endometriosis-associated pain.DesignRandomized, controlled study.SettingUniversity hospital.Patient(s)One hundred thirty-three women with relapse of endometriosis-related pain after previous endometriosis surgery.Intervention(s)Forty-six women were treated with GnRH analogue plus add-back therapy, 44 women were given GnRH analogue alone, and 43 women received estroprogestin, for 12 months.Main outcome measure(s)Pain evaluation by a visual analogue scale, quality of life in treated patients according to the SF-36 questionnaire, and occurrence of adverse effects, including bone mass density loss, at pretreatment, after 6 months of treatment, at the end of treatment (12 months), and 6 months after discontinuation of treatment.Result(s)Patients treated either with GnRH analogue alone or GnRH analogue plus add-back therapy showed a higher reduction of pelvic pain, dysmenorrhea, and dyspareunia than patients treated with oral contraceptive, whereas patients treated with add-back therapy showed a better quality of life, as assessed with the SF-36 questionnaire, and adverse effects rate than the other two groups.Conclusion(s)Add-back therapy allows the treatment of women with relapse of endometriosis-associated pain for a longer period, with reduced bone mineral density loss, good control of pain symptoms, and better patient quality of life compared with GnRH analogue alone or oral contraceptive.

My notes (saved in your browser only)

Condition tags

dysmenorrheadyspareuniaendometriosischronic_pelvic_pain

MeSH descriptors

Endometriosis Ethinyl Estradiol Gonadotropin-Releasing Hormone Norpregnenes Palliative Care Adult Bone Density Bone Density Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Drug Administration Schedule Drug Combinations Drug Therapy, Combination Dysmenorrhea Dysmenorrhea Dysmenorrhea Dyspareunia Dyspareunia Dyspareunia

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (33)

Cited by (50)

Source provenance

europepmc
last seen: 2026-07-31T06:09:14.520117+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:26.305326+00:00
License: CC0 · commercial use OK